Neuraxis, Inc. (NRXS)

Chart not available yet

Data will show when the stock starts trading on Feb 9, 2023.

Market Cap	40.66M
Revenue (ttm)	2.54M
Net Income (ttm)	-5.62M
Shares Out	5.08M
EPS (ttm)	-1.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About NRXS

Neuraxis is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. We are dedicated to advancing science with our proprietary PENFS (Percutaneous Electrical Nerve Field Stimulation) technology, which we developed. The IB-Stim is a PENFS system intended to be used in patients 11-18 years of age with functional abdominal pain associated with IBS. IB-Stim already has market clearance from the FDA for functional abdominal pain associated with IBS in children. FDA has classi...

• Industry: Health Care
• Sector: Biotechnology
• IPO Date: Feb 9, 2023
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: NRXS